Company / Free Cash Flow
Amneal Pharmaceuticals, Inc. Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
$269.9M
FY2025
5-year range
-$45.5M / $269.9M
FY2021-FY2025
Trend
+11.0%
vs FY2024
Sector context
#30 of 194
Health Care
What the data says
Amneal Pharmaceuticals, Inc.'s free cash flow of $270M is higher than 85% of companies in the Health Care sector (FY2025). Free Cash Flow has increased for 4 consecutive years, from -$45M in FY2021 to $270M in FY2025.
Based on SEC 10-K filings.
$270M in FY2025 with a 5-year CAGR of +10.1%. Top quartile in the Health Care sector.
Improved from $194M to $270M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- +143.5%
- 5-Year CAGR
- +10.1%
- 10-Year CAGR
- -
Sector benchmark
-42.6% below sector average
Key checks
Key Insights
- Amneal Pharmaceuticals, Inc.'s free cash flow has grown for 4 consecutive years.
- 5-year CAGR of +10.1%, indicating consistent growth.
- In FY2025, free cash flow increased 11.0% year-over-year.
- Ranks #30 out of 194 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 1.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $269.9M | +11.0% |
| FY2024 | $243.2M | +25.3% |
| FY2023 | $194.1M | +938.3% |
| FY2022 | $18.7M | +141.1% |
| FY2021 | -$45.5M | -127.2% |
| FY2020 | $167.1M | +19.9% |
| FY2019 | $139.4M | +1911.5% |
| FY2018 | -$7.7M | -105.5% |
| FY2017 | $139.4M | +1911.5% |
| FY2016 | -$7.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026